# Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

> **NCT02209779** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 167 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** BIBR 796 BS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02209779
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2002-06
- **Final completion:** —
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209779, "Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02209779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*